Key result
Depression and anxiety are linked to incident CVD and worse outcomes in existing heart disease.
Why the study?
There is ample evidence supporting depression and anxiety as risk factors for incident and recurrent cardiovascular disease, but challenges remain in treatment and prevention in primary care.
Depression and anxiety are significant risk factors for cardiovascular disease, emphasizing the need for primary care providers to screen for and manage these conditions to potentially mitigate cardiovascular risk.
Answers are grounded in this paper and cite their sources.
Mental health screening may improve CVD outcomes in primary care; extends meta-analytic evidence for integrated management.
Psychological stress has long been thought to impact physical health, particularly cardiovascular disease (CVD). Primary care providers are likely to encounter this in several ways. They may notice patients with mental health disorders, including depression or anxiety, develop CVD at younger ages or have a more challenging clinical course. In managing patients with established CVD, providers may find those with mental health comorbidities struggle with medication adherence and lifestyle recommendations and experience greater disease progression. These observations are supported by evidence demonstrating greater risk of incident and recurrent CVD in patients with depression and anxiety, two highly prevalent disorders often diagnosed and managed in primary care. We will provide a summary of this evidence, discussing epidemiologic studies, underlying mechanisms, clinical interventions and the role of primary care providers in preventing adverse cardiovascular outcomes in patients with depression and anxiety. There is ample evidence from diverse populations to support depression and anxiety as CVD risk factors. A 2017 meta-analysis linked major depressive disorder to a 72% increased risk for CVD, along with increases in specific categories of coronary heart disease (CHD), cerebrovascular disease, congestive heart failure and CVD-related death (1). Meta-analyses have also demonstrated an association between anxiety and greater risk of incident CHD, cardiac death, incident CVD and stroke (2,3). In addition to being risk factors for the development of CVD, depression and anxiety may lead to worse outcomes for patients with existing disease. A 2014 meta-analysis of nine studies of patients with heart failure found that depression was associated with a 51% increased risk of all-cause mortality (4), though a subsequent meta-analysis found that increased risk was only present in studies of patients with a mean age ≥65 (5). Among patients requiring revascularization, those with depression may be at higher risk for poor outcomes compared to those without depression. Meta-analyses have found that perioperative depression is associated with all-cause mortality following coronary artery bypass graft surgey (CABG) (6) and increased risk of adverse outcomes following percutaneous coronary intervention (PCI) (7). Depression may also increase the risk for adverse outcomes following stroke, with meta-analyses linking post-stroke depression to increased risk of stroke recurrence among those with ischaemic stroke and increased risk of all-cause mortality (8,9). Evidence supporting an association between anxiety and poor outcomes in patients with CVD is less robust. A meta-analysis of 44 prospective studies of patients with coronary artery disease found that anxiety increased the risk for mortality by 21%, though these findings were no longer significant after adjusting for potential confounders (10). Numerous studies have attempted to explore the pathogenesis of increased CVD risk in patients with depression and anxiety, though the bidirectional nature of some associations has made this challenging. Several studies have found an association between depression or anxiety and increased risk of developing obesity, diabetes, hypertension and dyslipidemia, all well-recognized risk factors for CVD. However, other studies have found evidence of the reverse association, with CVD risk factors indicating increased likelihood of future development of depression or anxiety (11). The biological consequences of depression and anxiety, including elevated inflammatory biomarkers and cytokines, may further increase CVD risk independent of traditional pathways, though these associations may be bidirectional as well (12). Other potential biological mechanisms include alterations in sympathetic nervous system function, increased oxidative stress, platelet activation and endothelial dysfunction (13). In addition to traditional risk factors and biological alterations, several behavioural and psychosocial factors may contribute to increased CVD risk. Patients with anxiety and depression are less likely to engage in exercise based on both self-report and objective data from accelerometer studies (14). Patients are also more likely to engage in other behaviours, such as tobacco or substance use that could increase CVD risk. While additional research is needed, it is clear that a combination of biological alterations and changes in behaviour can contribute to CVD risk in patients with depression and anxiety. The epidemiologic and mechanistic studies described above have prompted important research on treatments to target both mental health symptoms and cardiovascular risk. The majority of this has been done in patients with established heart disease (see summary of findings in Table 1). Meta-analyses of randomized controlled trials (RCTs) have linked mental health treatments to improvements in depression and anxiety as well as reductions in CHD events and cardiovascular mortality (15,16). However, interpretation is complicated by the multifactorial nature of many of the psychological interventions. Cardiac rehabilitation programs, which typically involve exercise training, health education and emotional support, improved depression, decreased CHD events and reduced total mortality (15). Another approach that has been tested is collaborative care for patients with comorbid CHD and depression, which involves close collaboration between medical and mental health providers. In a meta-analysis, this multidisciplinary team approach led to a short-term (<12 month) but not long-term reduction in major adverse cardiac events (17). Collaborative care also led to small but significant reductions in depression and anxiety symptoms and improved odds of depression remission. Summary of effect sizes from intervention studies with mental health and cardiovascular outcomes ARR, absolute risk reduction; CI, confidence interval; d, Cohen’s d; HR, hazard ratio; NNT, number needed to treat; OR, odds ratio; RR, relative risk; SMD, pooled standard mean difference. Summary of effect sizes from intervention studies with mental health and cardiovascular outcomes ARR, absolute risk reduction; CI, confidence interval; d, Cohen’s d; HR, hazard ratio; NNT, number needed to treat; OR, odds ratio; RR, relative risk; SMD, pooled standard mean difference. Studies have also investigated the impact of antidepressant use on cardiovascular risk, with mixed findings. Some cohort studies have found that patients using selective serotinin reuptake inhibitors (SSRIs) had a lower risk of myocardial infarction (MI) (18) and cardiac and cerebrovascular deaths (19). Additionally, in a double-blind RCT of 300 patients with acute coronary syndrome and depression, escitalopram was associated with lower risk of all-cause mortality, cardiac death, MI and PCI (20). However, a meta-analysis of 16 observational studies did not find an association between SSRIs and risk of CHD (21), and an observational study of cardiac rehab participants found that risk of major adverse cardiovascular outcomes was increased for patients taking SSRIs, as well as for patients taking tricyclic and atypical antidepressants but not for serotonin–norepinephrine reuptake inhibitors (SNRIs) (22). In summary, numerous RCTs have investigated the efficacy of antidepressant medications, behavioural therapies and collaborative care management models in patients with depression and existing CHD. These have demonstrated consistent improvements in mental health outcomes and safety for patients. However, the impact on cardiovascular outcomes has been mixed across treatment modalities. Far fewer trials have specifically targeted anxiety, and no trials have evaluated whether treatment of depression and anxiety could ‘prevent’ the development of CVD. Based on the evidence above, how can primary care providers intervene to prevent the negative cardiovascular consequences of depression and anxiety? The first step in this process is identification of at-risk patients through appropriate screening. Providers are stretched by numerous demands, but brief, validated screening instruments exist for depression and anxiety. The Patient Health Questionnaire-2 (depression) and Generalized Anxiety Disorder Questionnaire-2 (anxiety) (23,24) are two-item screens that can be given by providers or ancillary staff, have been widely tested in clinical populations and are incorporated into regular screens in health care systems. Providers can follow a positive screen with more detailed questions to establish a diagnosis and, depending on severity of symptoms and patient preference, treat them in primary care or initiate referrals for specialty mental health treatment. Models that integrate primary care and behavioural health may be particularly well suited for this task. Co-location of services and collaboration of providers can allow patients to better receive the psychoeducation and follow-up needed to help manage mental health concerns as well as primary and secondary prevention of cardiovascular disease. Providers also have an important role in patient education. Emphasizing the mind–body connection and the role that depression and anxiety play in cardiovascular health may help motivate patients to seek treatment. Lastly, though mechanisms are not thoroughly understood, providers can target known CVD risk factors and counsel patients. As described above, numerous epidemiologic studies have established a connection between depression, anxiety and elevated CVD risk. However, further work is needed to address several important knowledge gaps and translate evidence into improved outcomes for patients. First, challenges remain in approaches to treating depression and anxiety in primary care. Though numerous medications and behavioural therapies exist, not all patients will respond, and many patients will decline treatment or not complete recommended courses of therapy. Implementing treatments requires buy-in from patients and primary care staff, changes to workflows, acceptance from payers and additional resources that may be challenging for health care systems. Advances in virtual care and other implementation strategies may provide additional treatment options and expand the reach of programs. Second, there is a need for longitudinal studies with diverse patient populations to definitively establish the mechanisms linking depression and anxiety to CVD. This can yield new targets for reducing CVD risk to examine in future trials. As noted above, trials examining whether treatment of depression and anxiety can prevent the development of CVD could also inform future interventions. Finally, as mechanisms and best treatment strategies are defined, it will be important to educate patients and providers. The concepts of the mind–body connection and influence of psychological well-being on cardiovascular health are increasingly covered in the popular press and formally taught in medical programs. However, the level of knowledge of providers and patients on these topics remains unclear, as does the impact of improving knowledge on patient outcomes. Prior research suggests that the most successful approach will combine education with the implementation of guidelines and practice innovations (25). Using these strategies, primary care providers can work to improve the health, function and longevity of the many patients suffering from depression and anxiety. Funding: not applicable. Ethical approval: not applicable. Conflict of interest: on behalf of all authors, the corresponding author states that there is no conflict of interest. Disclaimer: the views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the University of California, San Francisco, the Department of Veterans Affairs, or the US Government. Not applicable.
No takes yet. Share an insight, caveat, or question.
Ryder et al. (2021) conducted a review in Depression, anxiety, and cardiovascular disease. Depression and anxiety was evaluated. Depression and anxiety are established risk factors for incident cardiovascular disease and are associated with worse outcomes in patients with existing heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: